Newer Therapies for Amyloid Cardiomyopathy (Q38920614)

7 September 2017

1 reference

title

Newer Therapies for Amyloid Cardiomyopathy (English)

1 reference

7 September 2017

3

Morie A Gertz

1 reference

7 September 2017

Rajshekhar Chakraborty

series ordinal

1

1 reference

PubMed ID

27497715

7 September 2017

Eli Muchtar

series ordinal

2

1 reference

7 September 2017

6 August 2016

1 reference

Current heart failure reports

7 September 2017

1 reference

7 September 2017

13

1 reference

7 September 2017

237-246

1 reference

7 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11897-016-0300-1

7 September 2017

0 references

cites work

Molecular mechanisms of amyloidosis

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Diagnosis and management of the cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Systemic amyloidosis in England: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Fibril in senile systemic amyloidosis is derived from normal transthyretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

The amyloidogenic V122I transthyretin variant in elderly black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Recent advances in the diagnosis and management of cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

21 January 2018

12 December 2020

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Left ventricular device implantation for advanced cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Cardiac transplantation for amyloid heart disease: the United Kingdom experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Liver transplantation in transthyretin amyloidosis: issues and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Diflunisal for ATTR cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-016-0300-1

Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens

21 January 2018

1 reference

12 December 2020

Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

12 December 2020

Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis

1 reference

12 December 2020

Clinical significance of histopathologic patterns of cardiac amyloidosis

1 reference

12 December 2020

Cardiac amyloidosis. Two cases with digitalis sensitivity

1 reference

12 December 2020

Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy

1 reference

12 December 2020

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

1 reference

12 December 2020

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

1 reference

12 December 2020

Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey

1 reference

12 December 2020

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

1 reference

12 December 2020

Antisense oligonucleotide therapy for TTR amyloidosis

1 reference

12 December 2020

10.1007/S11897-016-0300-1

Identifiers

DOI

1 reference

PubMed ID

27497715

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27497715